Content area

|
|

Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes

Forfatter(e)
Michael Einar Røder, Heidi Storgaard, Jørgen Rungby, Filip Krag Knop & Tina Vilsbøll Center for Diabetesforskning, Gentofte Hospital Ugeskr Læger 2016:178:V05160310
Reference: 
Ugeskr Læger 2016:178:V05160310
Blad nummer: 
Sidetal: 
2-6
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with type 2 diabetes
The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empa­gliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or metformin intolerance.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 29/11
2 kommentarer
af Stine Madsen-Østerbye | 29/11
1 Kommentar
af Kaj Seidelin | 29/11
6 kommentarer
af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar